Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients

被引:151
作者
Chen, LC
Lei, HY
Liu, CC
Shiesh, SC
Chen, SH
Liu, HS
Lin, YS
Wang, ST
Shyu, HW
Yeh, TM [1 ]
机构
[1] Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan
[2] Natl Cheng Kung Univ, Dept Microbiol & Immunol, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan
[3] Natl Cheng Kung Univ, Dept Pediat, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan
[4] Natl Cheng Kung Univ, Dept Publ Hlth, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan
[5] Fooyin Univ, Dept Med Technol, Kaohsiung, Taiwan
关键词
D O I
10.4269/ajtmh.2006.74.142
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Dengue virus infection can cause mild dengue fever (DF) or severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Cytokines are believed to be involved in the pathogenesis of dengue infection. However, the role of the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF) in dengue infection is unclear. In this study, serum levels of MIF in adult dengue patients with different disease severity and clinical outcome were determined and compared with the levels of other cytokines, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-10, and interferon gamma (IFN-gamma), in the same patients. Serum levels of MIF, IL-6, and IL-10, but not IFN-gamma or TNF-alpha, were higher in all DHF patients who died than in DHF survivors and DF patients. We conclude that in addition to IL-6 and IL-10, elevated levels of serum MIF are a potential predictor of disease severity and clinical outcome in dengue patients.
引用
收藏
页码:142 / 147
页数:6
相关论文
共 35 条
[1]   Systemic host inflammatory and coagulation response in the Dengue virus primo-infection [J].
Avila-Aguero, ML ;
Avila-Aguero, CR ;
Um, SL ;
Soriano-Fallas, A ;
Cañas-Coto, A ;
Yan, SB .
CYTOKINE, 2004, 27 (06) :173-179
[2]   Human cytomegalovirus-mediated induction of MIF in fibroblasts [J].
Bacher, M ;
Eickmann, M ;
Schrader, J ;
Gemsa, D ;
Heiske, A .
VIROLOGY, 2002, 299 (01) :32-37
[3]   Macrophage migration inhibitory factor [J].
Baugh, JA ;
Bucala, R .
CRITICAL CARE MEDICINE, 2002, 30 (01) :S27-S35
[4]   Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis [J].
Bozza, FA ;
Gomes, RN ;
Japiassú, AM ;
Soares, M ;
Castro-Faria-Neto, HC ;
Bozza, PT ;
Bozza, MT .
SHOCK, 2004, 22 (04) :309-313
[5]   Macrophage migration inhibitory factor: A regulator of innate immunity [J].
Calandra, T ;
Roger, T .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (10) :791-800
[6]   Protection from septic shock by neutralization of macrophage migration inhibitory factor [J].
Calandra, T ;
Echtenacher, B ;
Le Roy, D ;
Pugin, J ;
Metz, CN ;
Hültner, L ;
Heumann, D ;
Männel, D ;
Bucala, R ;
Glauser, MP .
NATURE MEDICINE, 2000, 6 (02) :164-170
[7]   High concentrations of circulating macrophage migration inhibitory factor in patients with severe blunt trauma: Is serum macrophage migration inhibitory factor concentration a valuable prognostic factor? [J].
Chuang, CC ;
Hung, CJ ;
Tsai, MC ;
Yeh, TM ;
Chuang, YC .
CRITICAL CARE MEDICINE, 2004, 32 (03) :734-739
[8]   Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease [J].
Donnelly, SC ;
Bucala, R .
MOLECULAR MEDICINE TODAY, 1997, 3 (11) :502-507
[9]   Diabetes-induced impairment of macrophage cytokine release in a rat model: Potential role of serum lipids [J].
Doxey, DL ;
Nares, S ;
Park, B ;
Trieu, C ;
Cutler, CW ;
Iacopino, AM .
LIFE SCIENCES, 1998, 63 (13) :1127-1136
[10]   Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome [J].
Gando, S ;
Nishihira, J ;
Kobayashi, S ;
Morimoto, Y ;
Nanzaki, S ;
Kemmotsu, O .
INTENSIVE CARE MEDICINE, 2001, 27 (07) :1187-1193